[go: up one dir, main page]

AR036189A1 - Anticuerpos de interleuquina-1beta - Google Patents

Anticuerpos de interleuquina-1beta

Info

Publication number
AR036189A1
AR036189A1 ARP020102764A ARP020102764A AR036189A1 AR 036189 A1 AR036189 A1 AR 036189A1 AR P020102764 A ARP020102764 A AR P020102764A AR P020102764 A ARP020102764 A AR P020102764A AR 036189 A1 AR036189 A1 AR 036189A1
Authority
AR
Argentina
Prior art keywords
1beta
antibodies
antibody
interleuquine
binds
Prior art date
Application number
ARP020102764A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR036189A1 publication Critical patent/AR036189A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente abarca anticuerpos de alta afinidad que neutralizan la actividad IL-1beta in vivo. Estos anticuerpos pueden ser utilizados para tratar varias enfermedades tales como artritis reumatoidea y osteoartritis. Reivindicación 1: Un anticuerpo que une las IL-1beta humanas maduras en donde el anticuerpo une al mismo epítope en las IL-1beta humanas maduras como el anticuerpo monoclonal de ratón Mu007 o el anticuerpo humanizado Hu007.
ARP020102764A 2001-07-26 2002-07-23 Anticuerpos de interleuquina-1beta AR036189A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30797301P 2001-07-26 2001-07-26
US31227801P 2001-08-14 2001-08-14

Publications (1)

Publication Number Publication Date
AR036189A1 true AR036189A1 (es) 2004-08-18

Family

ID=26976031

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020102764A AR036189A1 (es) 2001-07-26 2002-07-23 Anticuerpos de interleuquina-1beta

Country Status (8)

Country Link
US (1) US20050075488A1 (es)
EP (1) EP1423432A4 (es)
JP (1) JP2004536605A (es)
AR (1) AR036189A1 (es)
AU (1) AU2002355249A1 (es)
PE (1) PE20030282A1 (es)
SV (1) SV2003001183A (es)
WO (1) WO2003010282A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1481010A2 (en) * 2002-02-28 2004-12-01 Eli Lilly And Company Anti-interleukin-1 beta analogs
ES2567198T3 (es) * 2003-01-24 2016-04-20 Applied Molecular Evolution, Inc. Antagonistas de la IL-1 beta humana
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
WO2006081139A2 (en) 2005-01-26 2006-08-03 Abgenix, Inc. Antibodies against interleukin-1 beta
SI2314623T1 (sl) 2005-06-21 2012-11-30 Xoma Technology Ltd IL beta vezavna protitelesa in njihovi fragmenti
EP1896072A4 (en) * 2005-06-24 2013-01-09 Univ Duke SYSTEM FOR DIRECT HEALTH MANAGEMENT BASED ON HEAT-CONTROLLED BIOPOLYMERS
WO2007050607A2 (en) * 2005-10-26 2007-05-03 Novartis Ag Novel use of il-1beta compounds
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
MX2009006709A (es) * 2006-12-20 2009-07-02 Xoma Technology Ltd Tratamiento de enfermedades relacionadas con il-1beta.
CA2839162A1 (en) * 2006-12-20 2008-06-26 Xoma Technology Ltd. Methods for the treatment of il-1-.beta. related diseases
WO2009086003A1 (en) * 2007-12-20 2009-07-09 Xoma Technology Ltd. Methods for the treatment of gout
JP5607613B2 (ja) * 2008-06-06 2014-10-15 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー 関節リウマチの治療のための方法
WO2010028273A1 (en) 2008-09-05 2010-03-11 Xoma Technology Ltd. Methods for improvement of beta cell function
CA2797846A1 (en) 2010-05-07 2011-11-10 Xoma Technology Ltd. Methods for the treatment of il-1.beta. related conditions
US20110307788A1 (en) * 2010-06-15 2011-12-15 Microsoft Corporation Role-based presentation views
JP6320300B2 (ja) 2011-12-19 2018-05-09 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー 座瘡を治療するための方法
US10436795B2 (en) * 2016-09-16 2019-10-08 Institute For Cancer Research Carbon-detected NMR for mapping binding sites in intrinsically disordered regions of a protein

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
EP0569687B1 (en) * 1984-05-18 2002-08-21 New England Medical Center Hospitals, Inc. Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins
US5484887A (en) * 1984-06-19 1996-01-16 Immunex Corporation Homogeneous interleukin 1
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4935343A (en) * 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
WO1995001997A1 (en) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
US20020155114A1 (en) * 1998-08-31 2002-10-24 James D. Marks Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
WO2000053794A2 (en) 1999-03-12 2000-09-14 Agritope, Inc. Trait-associated gene identification method

Also Published As

Publication number Publication date
US20050075488A1 (en) 2005-04-07
JP2004536605A (ja) 2004-12-09
EP1423432A2 (en) 2004-06-02
SV2003001183A (es) 2003-07-29
EP1423432A4 (en) 2006-01-11
PE20030282A1 (es) 2003-03-25
WO2003010282A3 (en) 2004-02-12
WO2003010282A2 (en) 2003-02-06
AU2002355249A1 (en) 2003-02-17

Similar Documents

Publication Publication Date Title
AR036189A1 (es) Anticuerpos de interleuquina-1beta
EP4248996A3 (en) Anti-trem2 antibodies and methods of use thereof
EA200801027A1 (ru) Антитела против миостатина
PH12020551153A1 (en) Antibodies specific for cd70 and their uses
EA200970874A1 (ru) Антитела против склеростина
UA92504C2 (en) Anti-myostatin monoclonal antibody
ECSP14011269A (es) Formulaciones de anticuerpos y proteínas de alta concentración
NO982062L (no) Humaniserte antistoff mot humant gp39, sammensetninger inneholdende dette, samt terapeutisk anvendelse derav
AR021296A1 (es) Un anticuerpo humanizado especifico para 4-1bb humano y composiciones farmaceuticas que lo comprenden
EA200001041A1 (ru) Антитела к cd23, их производные и их терапевтическое применение
CL2011002744A1 (es) Anticuerpo anti il-17f monoclonal; composicion farmaceutica; uso de dicho anticuerpo para artritis reumatoide, enfermedad de crohn, psoriasis, esclerosis multiple, enfermedad pulmonar obstructiva cronica o asma en un sujeto.
NZ593428A (en) Therapeutic human anti-il-1r1 monoclonal antibody
NZ568769A (en) Human monoclonal antibodies against CD20
GR3026219T3 (en) Mouse monoclonal antibodies
CY1115671T1 (el) Θεραπευτικη χρηση αντισωματων anti-cs1
BRPI0418695A (pt) uso terapêutico de anticorpos anti-cs1
CY1108387T1 (el) Ανταγωνιστες ανασυνδυασμενης il-18 χρησιμοι στη θεραπεια παθησεων που εμφανιζονται με διαμεσολαβηση της il-18
TW200509930A (en) Methods and compositions for treating rheumatoid arthritis
ECSP044978A (es) ANTICUERPOS HUMANOS ANTAGONISTAS CONTRA hTNFSF13b
FI973120A0 (fi) Ihmisen gp39:n eri epitoopeille spesifisiä monoklonaalisia vasta-aineita ja menetelmiä niiden käyttämiseksi diagnosoinnissa ja terapiassa
HRP20080028A2 (en) Cd19 antibodies and their uses
CO4480111A1 (es) Anticuerpos monoclonales de mono especificos para humanos b7. y/o b7.2, formas primatizadas de los mismos, composicio- nes farmaceuticas que los contienen, y uso de los mismos co- mo inmunosupresantes
WO2003073982A3 (en) Anti-interleukin-1 beta analogs
UA98332C2 (ru) Гуманизированное антитело к cd44, которое опосредует цитотоксичность в отношении раковых клеток
BG101024A (bg) Моноклонално антитяло срещу сd44v6

Legal Events

Date Code Title Description
FA Abandonment or withdrawal